{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-21-003771","form_type":"8-K","ticker":"CMMB","cik":"0001534248","company_name":"Chemomab Therapeutics Ltd.","filed_at":"2021-12-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.944410+00:00","generated_at":"2026-06-28T03:49:37.022635+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Chemomab CMO Aharon resigns; Weiner appointed Interim CMO","bullets":["Dr. Arnon Aharon resigned as CMO effective Feb 1, 2022; will continue 60 days and as senior advisor.","Dr. David M. Weiner appointed Interim CMO effective immediately, part-time, based in U.S.","Dr. Weiner has 25+ years experience; previously CEO of Amathus Therapeutics, CMO at Lumos Pharma and aTyr Pharma.","Resignation not due to any disagreement with company or board.","Chemomab advancing CM-101 clinical programs in fibrotic/inflammatory diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-21-003771","json":"https://secwatch.observer/filing/0001178913-21-003771.json","markdown":"https://secwatch.observer/filing/0001178913-21-003771.md","text":"https://secwatch.observer/filing/0001178913-21-003771.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534248/000117891321003771/0001178913-21-003771-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534248/000117891321003771/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T03:49:37.022635+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3d73639754","claim":"Dr. Arnon Aharon resigned as Chief Medical Officer at Chemomab Therapeutics Ltd..","evidence_excerpt":"On November 29, 2021, Dr. Arnon Aharon notified Chemomab Therapeutics Ltd. (the “Company”) of his resignation as its Chief Medical Officer, which will enter into effect on February 1, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891321003771/0001178913-21-003771-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}